Diagnosis of aHUS posthumous recurrence is a doubtful disease in the field of blood tumours, with clinical performance being complex and often involving multi-systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of aHUS requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching the needs of a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised development of treatment programs for treatment and management of aHUS post-transplant recurrence, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustment according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of aHUS post-transplant recurrence. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.